MONTREAL, QUEBEC--(Marketwire - October 24, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted in the laboratories of Drs. Channing J. Der and Adrienne D. Cox, University of North Carolina at Chapel Hill, and presented today at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
